Comparison between Alkem Laboratories IPO and TeamLease IPO.
Alkem Laboratories IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while TeamLease IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Alkem Laboratories IPO is up to ₹1,347.76 Cr whereas the issue size of the TeamLease IPO is up to ₹423.68 Cr. The final issue price of Alkem Laboratories IPO is ₹1,050.00 per share and of TeamLease IPO is ₹850.00 per share.
| Alkem Laboratories IPO | TeamLease IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹10 per share |
| Issue Price (Lower) | ₹1,020.00 per share | ₹785.00 per share |
| Issue Price (Upper) | ₹1,050.00 per share | ₹850.00 per share |
| Issue Price (Final) | ₹1,050.00 per share | ₹850.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹100.00 per share | ₹0.00 per share |
| Market Lot Size | 14 shares | 15 shares |
| Fresh Issue Size | 0 shares | 17,64,705 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹150.00 Cr |
| OFS Issue Size | 1,28,53,442 shares | 32,19,733 shares |
| OFS Issue Size (Amount) | up to ₹1,347.76 Cr | up to ₹273.68 Cr |
| Issue Size Total | 1,28,53,442 shares | 49,84,438 shares |
| Issue Size Total (Amount) | up to ₹1,347.76 Cr | up to ₹423.68 Cr |
Alkem Laboratories IPO opens on Dec 08, 2015, while TeamLease IPO opens on Feb 02, 2016. The closing date of Alkem Laboratories IPO and TeamLease IPO is Dec 10, 2015, and Feb 04, 2016, respectively.
| Alkem Laboratories IPO | TeamLease IPO | |
|---|---|---|
| Anchor Bid Date | Dec 07, 2015 | Feb 01, 2016 |
| Issue Open | Dec 08, 2015 | Feb 02, 2016 |
| Issue Close | Dec 10, 2015 | Feb 04, 2016 |
| Basis Of Allotment (Tentative) | ||
| Initiation of Refunds (Tentative) | ||
| Credit of Share (Tentative) | ||
| Listing date (Tentative) | Dec 23, 2015 | Feb 12, 2016 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Alkem Laboratories IPO P/E ratio is , as compared to TeamLease IPO P/E ratio of .
| Alkem Laboratories IPO | TeamLease IPO | |
|---|---|---|
| Financials | ||
| Promoter Shareholding (Pre-Issue) | 70.87 | 51.86 |
| Promoter Shareholding (Post-Issue) | 66.23 | 19.99 |
| P/E Ratio | ||
| Market Cap | ₹12554.33 Cr. | ₹1453.23 Cr. |
| ROE | ||
| ROCE | ||
| Debt/Equity | ||
| EPS | ||
| RoNW | 15.4 |
In the Alkem Laboratories IPO Retail Individual Investors (RII) are offered 43,94,086 shares while in TeamLease IPO retail investors are offered 43,94,086 shares. Qualified Institutional Buyers (QIB) are offered 25,10,906 shares in Alkem Laboratories IPO and 14,92,345 shares in TeamLease IPO.
| Alkem Laboratories IPO | TeamLease IPO | |
|---|---|---|
| Anchor Investor Reservation | 37,66,358 shares | 22,38,498 shares |
| Market Maker Reservation | ||
| QIB | 25,10,906 shares | 14,92,345 shares |
| NII | 18,83,179 shares | 7,46,165 shares |
| RII | 43,94,086 shares | 4,97,430 shares |
| Employee | 2,98,913 shares | 10,000 shares |
| Others | ||
| Total | 1,28,53,442 shares | 49,84,438 shares |
Alkem Laboratories IPO subscribed 31.31x in total, whereas TeamLease IPO subscribed 38.30x.
| Alkem Laboratories IPO | TeamLease IPO | |
|---|---|---|
| QIB (times) | 57.19x | 28.95x |
| NII (times) | 129.96x | 190.68x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 3.17x | 10.93x |
| Employee (times) | 0.67x | 1.39x |
| Other (times) | ||
| Total (times) | 31.31x | 38.30x |
